Sanofi (SAN FP) and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Sanofi's phase 2b trial results for duvakitug showing durable efficacy in ulcerative colitis and Crohn's disease may boost investor confidence in its product pipeline and market position.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Commander of Iran's IRGC says if it comes to closing the Strait of Hormuz, this force will carry out the operation in the shortest possible time

Part of strait of Hormuz is closed for hours due to drills, Iranian TV reports

Sanofi (SAN FP) and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

The negotiations on Ukraine in Geneva will start within an hour, a part of the Russian delegation will also arrive at the negotiation site soon, reports suggest

EU launches full-scale probe into Shein, under the Digital Service Act

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Clinical milestones like this can drive stock momentum and have positive read-through for the broader pharmaceuticals sector, particularly if they lead to regulatory submissions or partnerships.

Related headlines

The whole workspace, free to try.

Try it free